Biology Reference
In-Depth Information
28. Vandenberghe LH, Wilson JM, Gao G (2009)
Tailoring the AAV vector capsid for gene ther-
apy. Gene Ther 16(3):311-319
29. Bankiewicz KS et al (2000) Convection-
enhanced delivery of AAV vector in parkinso-
nian monkeys; in vivo detection of gene
expression and restoration of dopaminergic
function using pro-drug approach. Exp Neurol
164(1):2-14
30. Bankiewicz KS et al (2006) Long-term clinical
improvement in MPTP-lesioned primates after
gene therapy with AAV-hAADC. Mol Ther
14(4):564-570
31. Forsayeth JR et al (2006) A dose-ranging
study of AAV-hAADC therapy in Parkinsonian
monkeys. Mol Ther 14(4):571-577
32. Hadaczek P et al (2010) Eight years of clinical
improvement in MPTP-lesioned primates after
gene therapy with AAV2-hAADC. Mol Ther
18(8):1458-1461
33. Muramatsu S et al (2002) Behavioral recovery
in a primate model of Parkinson's disease by
triple transduction of striatal cells with adeno-
associated viral vectors expressing dopamine-
synthesizing enzymes. Hum Gene Ther
13(3):345-354
34. Lozano AM, Dostrovsky J, Chen R, Ashby P
(2002) Deep brain stimulation for Parkinson's
disease: disrupting the disruption. Lancet
Neurol 1(4):225-231
35. Emborg ME et al (2007) Subthalamic glu-
tamic acid decarboxylase gene therapy: changes
in motor function and cortical metabolism. J
Cereb Blood Flow Metab 27(3):501-509
36. Feigin A et al (2007) Modulation of metabolic
brain networks after subthalamic gene therapy
for Parkinson's disease. Proc Natl Acad Sci
USA 104(49):19559-19564
37. LeWitt PA et al (2011) AAV2-GAD gene ther-
apy for advanced Parkinson's disease: a double-
blind, sham-surgery controlled, randomised
trial. Lancet Neurol 10(4):309-319
38. Eslamboli A et al (2005) Continuous low-level
glial cell line-derived neurotrophic factor deliv-
ery using recombinant adeno-associated viral
vectors provides neuroprotection and induces
behavioral recovery in a primate model of
Parkinson's disease. J Neurosci 25(4):769-777
39. Kells AP et al (2010) Regeneration of the
MPTP-lesioned dopaminergic system after
convection-enhanced delivery of AAV2-
GDNF. J Neurosci 30(28):9567-9577
40. Kordower JH et al (2006) Delivery of neur-
turin by AAV2 (CERE-120)-mediated gene
transfer provides structural and functional neu-
roprotection and neurorestoration in MPTP-
treated monkeys. Ann Neurol 60(6):706-715
41. Berton O et al (2009) Striatal overexpression
of DeltaJunD resets L-DOPA-induced dyski-
nesia in a primate model of Parkinson disease.
Biol Psychiatry 66(6):554-561
42. Ciron C et al (2009) Human alpha-iduronidase
gene transfer mediated by adeno-associated
virus types 1, 2, and 5 in the brain of nonhu-
man primates: vector diffusion and biodistri-
bution. Hum Gene Ther 20(4):350-360
43. McFarland NR, Lee JS, Hyman BT, McLean
PJ (2009) Comparison of transduction effi -
ciency of recombinant AAV serotypes 1, 2, 5,
and 8 in the rat nigrostriatal system. J
Neurochem 109(3):838-845
44. Taymans JM et al (2007) Comparative analysis
of adeno-associated viral vector serotypes 1, 2,
5, 7, and 8 in mouse brain. Hum Gene Ther
18(3):195-206
45. Colle MA et al (2010) Effi cient intracerebral
delivery of AAV5 vector encoding human
ARSA in non-human primate. Hum Mol
Genet 19(1):147-158
46. Dodiya HB et al (2010) Differential transduc-
tion following basal ganglia administration of
distinct pseudotyped AAV capsid serotypes in
nonhuman primates. Mol Ther 18(3):579-587
47. Hadaczek P et al (2009) Transduction of non-
human primate brain with adeno-associated
virus serotype 1: vector traffi cking and immune
response. Hum Gene Ther 20(3):225-237
48. Markakis EA et al (2010) Comparative trans-
duction effi ciency of AAV vector serotypes 1-6
in the substantia nigra and striatum of the pri-
mate brain. Mol Ther 18(3):588-593
49. Sanchez CE et al (2011) Recombinant adeno-
associated virus type 2 pseudotypes: compar-
ing safety, specifi city, and transduction
effi ciency in the primate striatum. Laboratory
investigation. J Neurosurg 114(3):672-680
50. Yasuda T et al (2007) Neuronal specifi city of
alpha-synuclein toxicity and effect of Parkin
co-expression in primates. Neuroscience
144(2):743-753
51. Inagaki K et al (2007) DNA palindromes with
a modest arm length of greater, similar 20 base
pairs are a signifi cant target for recombinant
adeno-associated virus vector integration in
the liver, muscles, and heart in mice. J Virol
81(20):11290-11303
52. Zhang H et al (2011) Several rAAV vectors
effi ciently cross the blood-brain barrier and
transduce neurons and astrocytes in the neona-
tal mouse central nervous system. Mol Ther
19(8):1440-1448
53. Foust KD et al (2009) Intravascular AAV9
preferentially targets neonatal neurons and
adult astrocytes. Nat Biotechnol 27(1):59-65
54. Duque S et al (2009) Intravenous administra-
tion of self-complementary AAV9 enables
transgene delivery to adult motor neurons.
Mol Ther 17(7):1187-1196
55. Dominguez E et al (2011) Intravenous
scAAV9 delivery of a codon-optimized SMN1
sequence rescues SMA mice. Hum Mol Genet
20(4):681-693
Search WWH ::
Custom Search